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Objective. The objective of this study was to evaluate the regression of temporomandibular pain as a result of intra-articular
injections of platelet-rich plasma (PRP) to patients with temporomandibular joint dysfunction previously subjected to prosthetic
treatment. Materials and Methods. The baseline study material consisted of 10 patients, both males and females, aged 28 to 53
years, previously treated due to painful temporomandibular joint dysfunction using occlusal splints. All patients were carried out
to a specialist functional assessment of the dysfunction using the Polish version of the RDC/TMD questionnaire axis I and II.
Intra-articular injections were preceded by a preparation of PRP. The injection sites were determined by the method used during
arthroscopic surgical procedures. Following aspiration, 0.5mL of plasma was injected into each temporomandibular joint. Results.
The comparison of the intensity of pain during all examinations suggests a beneficial effect of the procedure being performed as
the mean VAS score was 6.5 at examination I, 2.8 at examination II, and 0.6 at examination III. Conclusion. Application of the
intra-articular injections of platelet-rich plasma into the temporomandibular joints has a positive impact on the reduction of the
intensity of pain experienced by patients treated for temporomandibular joint dysfunction.
1. Introduction
A number of conservative methods are used in the treatment
of temporomandibular joint dysfunction pain syndrome,
including occlusal splints of various designs, supportive phys-
ical therapy procedures, rehabilitation involving muscular
training, and specialist psychological support [1–10].
Intra-articular administration of medications is an estab-
lished method of treatment, particularly in orthopedic and
rheumatic disorders associated with pain, effusion, inflam-
mation of cartilage, and bone and joint capsules as well as
fibrous adhesions. Currently, agents used for intra-articular
injection within the temporomandibular joint regions
include hyaluronic acid and steroids [11, 12].
Although autogenous platelet-rich plasma (PRP) concen-
trates were developed in the 1970s, the medical use of these
materials was facilitated only by subsequent technological
advances, particularly by progress in medical instrumenta-
tion. In 1997,Whitman et al. were the first to present amethod
for preparation and use of platelet-rich plasma to accelerate
healing processes. Centrifugation of full autogenous blood
yields a platelet concentrate with platelet concentration of ca.
1million cells per cubicmillimeter of plasma.The concentrate
is produced in the process of collecting peripheral vein blood
(most commonly from the ulnar vein) directly from patients,
with blood being centrifuged during the procedure. To date,
platelets were demonstrated to contain more than 30 growth
factors, themost important of them being the platelet derived
growth factor (PDGF), transforming growth factor (TGF),
epidermal growth factor (EGF), insulin-like growth factor
(IGF), and vasoendothelial growth factor (VEGF) [13–21].
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Platelets are anuclear, flat disc-shaped cells formed in
bone marrow; about 30% of all platelets are found in the
spleen. The life span of platelet cells ranges from 8 to 12 days;
cells are eliminated by the mononuclear phagocyte system.
When in the interphase, platelets have no thrombogenic
potential; thrombin is required for their activation which
involves a change in the shape and the release of granules.
Themain function of the platelets is the control of hemostasis.
Platelets form hemostatic plugs at injury sites, participating
in blood coagulation processes. Wound healing starts with
platelet thrombus formation, platelet degranulation, and the
release of growth factors. The next stage involves fibroplasia
and angiogenesis followed by the synthesis of structural
connective tissue elements. This leads to increased resistance
to wound disruption and then to scar remodeling. New
collagen is generated owing to chemotactic and mitogenic
effects of FGF on fibroblasts, stimulating proliferation and
differentiation of keratinocytes thanks to the presence of
highly concentrated growth factors [12, 16, 18].
Platelet-derived growth factors contained in the concen-
trate are peptides that stimulate proliferation, differentiation,
and migration of cells. These properties determine the use-
fulness of growth factors in the healing process. Most growth
factors presentwithin the platelet-rich plasmahavemitogenic
properties leading to an increase in the repair cell counts.
Growth factors derived from centrifuged blood were used
for the first time by Knighton in patients with chronic skin
ulcerations [18].
Platelet-rich plasma contains proteins that are responsible
for cell adhesion, namely, fibrin, fibronectin, and vitronectin.
It stimulates tissue regeneration processes by stimulating
fibroblasts to produce structural proteins for use in forma-
tion of new collagen and elastin, support of remodeling
and angiogenesis (formation of new vessels), and activation
of mesenchymal stem cells. PRP is widely used in surgi-
cal procedures, in the treatment of burns and extensive,
difficult-healing wounds, orthopedic ligament injuries, and
connective tissue injuries. An additional advantage of this
method is the safety of the material and a zero possibility of
hypersensitivity to injected plasma. It should be kept in mind
that blood and plasma may be carriers of pathogens such as
HIV, CMV, EBV, or HCV, and therefore precautions should
be used consisting of appropriate staff apparel and patient
behavior [13–18, 21, 22]. (Consent of the Bioethics Committee
Number KBET/125/L/2013.)
The objective of this study was to evaluate the regression
of temporomandibular pain as a result of intra-articular
injections of platelet-rich plasma to patients with temporo-
mandibular joint dysfunction previously subjected to pros-
thetic treatment.
2. Materials and Methods
The baseline study material consisted of 10 patients, both
males and females, aged 28 to 53 years, previously treated
using occlusal splints, who reported at the Consulting
Room of Temporomandibular Joint Dysfunctions of the
Figure 1: Disposable closed set for blood collection.
Department of Dental Prosthetics of the Jagiellonian Uni-
versity Medical College in Krakow between 01.09.2013 and
20.05.2014 due to painful dysfunction of the stomatognathic
system.
All patients were carried out to a specialist functional
assessment of the masticatory organ using the Polish version
of the RDC/TMD questionnaire axis I and II (examination
I). The following parameters were analyzed in detail for the
purposes of this study: changes in the intensity of pain as
reported by the patients with regard to temporomandibular
joints and stomatognathic system muscles, pain intensity
characteristics, level of impairment, and grade of chronic pain
[23, 24].
The assessment involved also a subjective assessment of
painwithin the stomatognathic systemmuscles and temporo-
mandibular joints, evaluation of the range and symmetry of
mandible motion, acoustic symptoms within the temporo-
mandibular joints, and the impact of the masticatory organ
health on overall well-being [1, 3, 23].
The inclusion criteria included temporomandibular joint
dysfunction pain manifested as lack of coordination in
operation of articular heads and disc (disc translocation with
or without disc blockade/crackling sounds/) and dysfunc-
tions presenting with excessive masticatory muscle tone as
the dominant problem and lack of benefits from previous
treatment methods. All subjects reported that the pain had
sustained for at least 3 months and that they continued the
prosthetic treatment.
The exclusion criteria included poor overall health,
unwillingness to participate, numerous dental defects, diag-
nosis of a connective tissue disease, and dysfunctions clas-
sified as RDC/TMD groups IIIb and IIIc. Contraindications
associated with the use of platelet-rich plasma (platelet func-
tion disorders, fibrinogen deficiency, and anticoagulation
treatment) were also taken into account [1, 3, 5, 6, 11, 23, 24].
Intra-articular injections of platelet-rich plasma were
preceded by collection of peripheral blood from the ulnar
vein of the patient in accordance witj the procedures in
force using single-use, closed vacuum systems and glass tubes
with sodium citrate as an anticoagulant (Figure 1). After
mixing the collected blood exactly with the citrate using
rotational movements, an even number of tubes were placed
in a centrifuge rotor. Centrifugation parameters were set to
3,200 rpm, and the centrifugation time was 12 minutes. After
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Figure 2: Scheme of place for intra-articular injection.
Table 1: Categories of clinical form according to the RDC/TMD.
Patient 1 2 3 4 5 6 7 8 9 10
Clinical form IIIa IIb IIa IIIa IIa IIIa IIa IIIa IIa Ia
separation of the erythrocytic mass and the platelet-poor and
platelet-rich plasma layered directly above the erythrocytes,
the platelet-rich plasma was aspirated with caution into a
separate syringe. Thus prepared concentrate was ready for
injection into the temporomandibular joint regions [18, 24–
27].
The injection sites were determined by the method used
during arthroscopic surgical procedures within the temporo-
mandibular joints. Patients were prepared for the procedure
by a line being drawn on their skin between the earlobe
and the outer eye corner. Three segments were marked at
10mm intervals starting from the earlobe. The lengths of
the lines were 3mm (first line), 5mm (second line), and
7mm (third line). The platelet-rich plasma injection site was
marked by the tip of the third line corresponding to the
upper compartment and retrodiscal zone (Figure 2). The
skin at the injection site was washed with a disinfectant
to decontaminate the field. Injections were made in the
determined point with the mandible abducted. Following
aspiration, 0.5mL of plasma was injected into each temporo-
mandibular joint. The skin was disinfected once again after
the injection. Patients were informed about the possibility
of experiencing an unpleasant and transient sensation of
fullness or compression in the joint regions. Clinical follow-
up was performed 7 days (examination II) and 6 weeks
(examination III) after the procedure [18, 28–30].
The following parameters were assessed in the special-
ist baseline examination and the follow-up examinations
using the RDC questionnaire: the presence and intensity of
spontaneous and palpation-induced pain within temporo-
mandibular joints and masticatory muscles, the range and
symmetry of mandible motion, abduction trajectory, and the
presence of acoustic symptoms within temporomandibular
joints during all mandible movements and accompanying
symptoms such as squeaking sounds and tinnitus in ears.
In one case, classified as RDC group IIb, active unblocking
of the articular joint was first performed; the patient was
subsequently qualified for platelet-rich plasma injection [8,
23].
The results were subjected to statistical analysis using the
basic procedures such as determination of means, standard
deviations, medians, and post hoc ANOVA Friedmana sta-
tistical significance test.
3. Results
The group of patients qualified for the study consisted of
two males and eight females. The mean age was 37.6 years.
According to the results of baseline examinations, the patients
reported for prosthetic treatment for the following reasons:
pain within one or both temporomandibular joints, sponta-
neous or occurring at mandible movements, chewing, tight
jaw occlusion, or joint palpation. The pain was located in
the joints or the masticatory muscles, radiating into the
temporal and cranial region in 2 cases. Joint crackling sounds
were heard upon mandible movements by 4 patients, while
a reduced range of mandible abduction was observed in 1
patient. The following diagnoses were made on the basis of
RDC/TMD questionnaire axis I survey: 1 case of group I a, 4
cases of group II a, case of group II b, and 4 cases of group III
a (Table 1).
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Table 2: (a) Assessment of pain intensity by VAS Scale during
subsequent investigation. (b) Average values of pain scoring in the
subsequent studies in the statistical calculation.
(a)
Investigation Patient
1 2 3 4 5 6 7 8 9 10
Invest. I 10 7 6 7 6 7 6 7 5 4
Invest. II 4 4 2 2 3 4 3 4 1 1
Invest. III 0 1 1 0 0 2 1 1 0 0
(b)
ANOVA Friedmana
Chi kwad. ANOVA (𝑁 = 10, df 2) = 20,0 𝑃 = 0,00005 0
Mean value Standard deviation
Invest. I 6.50 1.58
Invest. II 2.80 1.23
Invest. III 0.60 0.70
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Figure 3: Values of pain scoring in the subsequent studies presented
graphically.
The comparison of the intensity of temporomandibular
joint and masticatory muscles pain at baseline and follow-
up examinations suggests a beneficial effect of the proce-
dure being performed as the mean VAS score was 6.5 at
examination I, 2.8 at examination II, and 0.6 at examination
III. The result of subsequent investigation differs in the
statistically significant way (Tables 2(a) and 2(b), Figures 3
and 4). It should be mentioned that the question regarding
the presence of pain within the last 6 months was answered
positively by all patients and the minimum score marked at
the VAS scale was 5. Acoustic symptoms observed within
the temporomandibular joints in 4 cases (group II a) at
examination I were experienced by only one patient in the
final examination.
Table 3 presents the results of the RDC/TMD (axis II)
evaluation of chronic pain in the study group, assessing
the characteristics of pain intensity, impairment level, and
chronic pain grade. The results showed grade I chronic pain
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Standard error
Standard deviation
Chi kwadrat ANOVA (N= 10, df 2) = 20,0 P = 0,00005
Figure 4: Average values of pain scoring in the subsequent studies
in the statistical calculation, presented graphically.
in 2 subjects, grade II chronic pain in 4 subjects, grade III
chronic pain in 1 subject, and grade IV chronic pain in 3
subjects.
4. Discussion
Chronic facial pain is a common cause of impairment in the
everyday activities of patients and requires numerous thera-
peutic procedures being initiated by physicians of different
dental specialties as well as by neurologists, laryngologists,
maxillofacial surgeons, and psychiatrists.This suggests a need
for interdisciplinary treatment due to the complex character
of complaints. Temporomandibular joint pain is a special
problem as the mandible motion upon chewing and talking
constitutes a stimulus for a significant increase in the pain
being experienced [1–10, 24, 29, 31–34].
Acoustic symptoms and tenderness on palpation (asso-
ciated with hyperactivity) of mandible lifting muscles are
an evidence of overloads located within the posterior disc
ligament (strain, swelling, and corrugation). The area is
poorly accessible for application of healing-promoting drugs
and the physical therapy procedures applied in these cases are
not always satisfactory.
Many researchers studying PRP treatments highlight the
high efficacy of this method of management of musculoar-
ticular disorders and its safety due to the use of autologous
material as well as the low costs of treatment [12–22, 25–
28, 30, 35–57].
Daif compared the efficacy of intra-articular injections
within the upper temporomandibular joint compartment and
additional injections in the articular capsule region points
out the superiority of the latter method for the treatment
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Table 3: The results of scoring protocol for grade chronic pain.
Patient Characteristic pain intensity (CPI) Disability points CPGC [grade]
I Invest. II Invest. III Invest.
1 100 80 66 5 IV
2 90 73 63 6 IV
3 43 33 30 0 I
4 63 46 40 2 II
5 63 53 43 1 II
6 70 60 53 3 III
7 40 26 23 0 I
8 70 60 50 5 IV
9 66 53 46 3 II
10 60 46 43 2 II
CPGC: chronic pain grade classification.
of dysfunctions involving disc translocation with no disc
blocking [58]. PRP is commonly used in dentistry procedures
such as filling bone defects with trabecular bone chips
mixed with platelet-rich plasma. The results of follow-up
histomorphometric examinations performed 12 weeks after
the procedure revealed higher bone density in patients hav-
ing undergone the transplant of trabecular bone transplant
combined with PRP [13].
Today, the use of platelet-rich plasma has been expanded
no include numerous indications after orthopedic surgeries
to treat sports-related injuries. PRP is widely used for tissue
healing inmany anatomical regions aswell as in the treatment
of pathological lesions of bone, cartilage, ligament, and
muscle tissues.The popularity of this novel treatmentmethod
triggered a rapid increase in research. However, differences
in application techniques and PRP compositions make com-
parisons of efficacy results difficult. Potential complications
following the procedures involving PRP administration are
mild and therefore this method of treatment appears to
be safe. It brings various potentially positive effects for the
damagedmusculoskeletal system tissues. Platelet-rich plasma
injection is used with increasing frequency in reconstructive
orthopedic procedures (tennis elbow, knee injuries, healing of
meniscus, cruciate ligaments, and Achilles tendons), muscle
injuries, dental surgeries, and implantations [12–22, 27, 30,
35–40, 45–51]. As highlighted by Middleton et al., PRP
injections promote optimization of healing environment
and facilitate earlier functional rehabilitation of joints [42].
Studies conducted by Paoloni et al. and Pelletier et al. demon-
strated high efficacy of PRP injections in the anterior cruciate
ligament region in the knee and food injuries [46, 47]. Filardo
et al. reported the use of platelet-rich plasma in the treatment
of intra-articular cartilage injuries and knee inflammations;
the treatment was reported to cause rapid reduction of pain
and quick recovery of functional capability [27]. Studies
conducted by Sundman et al. demonstrated significant anti-
inflammatory properties of plasma [50]. Proper healing is
also influenced by appropriate preparation of platelet-rich
plasma, starting from proper collection of peripheral blood
and optimum centrifugation parameters and ending at the
administration procedure itself [12–22, 25–28, 30, 35–58].
A separate opinion suggesting the lack of confirmed
benefits of PRP on musculoarticular tissue healing has been
presented by Willits et al., who claim that the review of
PubMed and Medline data performed in April 2013 does
not warrant any positive opinions on the clinical use of this
method [59].
The results of our preliminary research suggest beneficial
effects of platelet-rich plasma in intra-articular injections as
a supplement to the basic prosthetic treatment of temporo-
mandibular joint dysfunction. The reduction in pain and
gradual restoration of functional capabilities of the stom-
atognathic system as the result of the treatment of interest
raises hopes that future studies would lead to establishment
of appropriate management algorithms.
5. Conclusion
Conclusions are as follows.
(1) Additional intra-articular injections of platelet-rich
plasma into the temporomandibular joints have a
positive impact on the reduction in the intensity of
pain experienced by patients treated for temporo-
mandibular joint dysfunction.
(2) Determination of appropriate treatment algorithm
making use of intra-articular injection in patients
with temporomandibular joint dysfunction pain
requires further studies and longer follow-up of the
study group.
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